Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primates

19 Jun 2021

Abstract excerpt

A safe and effective vaccine is critical to combat the COVID-19 pandemic. Here, we developed a trimeric SARS-CoV-2 receptor-binding domain (RBD) subunit vaccine candidate that simulates the natural structure of the spike (S) trimer glycoprotein. Immunization with the RBD trimer-induced robust humoral and cellular immune responses, and a high level of neutralizing antibodies was maintained for at least 4.5 months....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Influenza Virus Research Studies
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34179862
DOI: 10.1016/j.xinn.2021.100140

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A recombinant receptor-binding domain in trimeric form generates protective immunity against SARS-CoV-2 infection in nonhuman primatesPMID 34179862Read ↗

Incorporation of SARS-CoV-2 spike NTD to RBD protein vaccine improves immunity against viral variantsSemantic proximity Read ↗

Incorporation of Sars-Cov-2 Spike Ntd to Rbd-Based Vaccine Improves Immunity and Protection Against Viral VariantsSemantic proximity Read ↗

SARS-COV-2 Recombinant Receptor-Binding-Domain (RBD) Induces Neutralising Antibodies Against Variant Strains of SARS-CoV-2 and SARS-CoV-1Semantic proximity Read ↗

Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaques.Semantic proximity Read ↗

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity Read ↗

Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccineSemantic proximity Read ↗

Targeting SARS-CoV-2 receptor-binding domain to cells expressing CD40 improves protection to infection in convalescent macaquesSemantic proximity Read ↗

Protection of the receptor binding domain (RBD) dimer against SARS-CoV-2 and its variants.Semantic proximity Read ↗

S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primatesSemantic proximity Read ↗

SARS-CoV-2 preS dTM vaccine booster candidates increase functional antibody responses and cross-neutralization against SARS-CoV-2 variants of concern in non-human primatesSemantic proximity Read ↗

saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concernSemantic proximity Read ↗

Design of a mutation-integrated trimeric RBD with broad protection against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.